fyi
https://www.livewiremarkets.com/wires/telix-pharma-lighting-up-cancer-care
Our investment thesis.We maintain our OVERWEIGHT rating and $8.50/share price target on Telix. With proof of product sales now demonstrated, Telix move out of the pre-revenue biotech space and into a commercial business with a capacity to meet, and potentially exceed revenue forecasts. Through continued investment into their pipeline of both diagnostic and therapy products in prostate, kidney and brain cancer, ILLUCCIX only represents the first opportunity for Telix. With a near-term readout of their Phase III trial in kidney cancer, we anticipate that Telix’s next driver of growth, may not be too far away.
https://bit.ly/3d6frpJJefferies, Wilsons, Taylor Collison and Bell Potter all rate the stock as a buy, with valuations between $8.50 and $10.70.
Wilsons estimated Telix sold 3000 doses of Illuccix in April-June and forecast total sales could reach $174.3 million in the year ending in June 2023 which are projected to rocket to $262.6 million in 2024.
fyihttps://www.livewiremarkets.com/wires/telix-pharma-lighting-up...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.44 |
Change
-0.320(1.54%) |
Mkt cap ! $6.840B | |||
| Open | High | Low | Value | Volume |
| $20.79 | $21.00 | $20.22 | $19.41M | 945.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $20.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.46 | 45 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |